Anavex Life Sciences Corp (AVXL)

[Investor2014]

Another thing to say as we go armless into pre-specified subgroup analysis is that here S1R mRNA expression becomes very useful along with the independently established fact that expression levels eventually drop in line with disease progression.

Correlating responder subgroups with positive S1R expression change and corresponding improvement in some/all of the other pre-specified biomarkers may be an acceptable override of dose arm correlated response.

This is why I am staying invested in $AVXL even if the outcome is most likely a next P3 Precision Medicine trial based on clearly understood responder characteristics.